On October 29, Kodiak Sciences Inc. rose 5.73% in Regular Trading, trading at $103.39 per share, with turnover of $16.24 million.
The move coincided with continued market digestion of a large insider purchase by director and major shareholder Felix Baker, alongside previously disclosed positive Phase 3 data for the company’s retinal disease drug candidates.
Background context shows Baker acquired about $157 million of shares in late September through affiliated entities at $80.85 per share, described as his largest purchase to date, further increasing the Baker-related stake. Separately, the company said Zenkuda and tabirafusp-ted met primary endpoints in a Phase 3 wet AMD study, and it plans to submit Zenkuda data from five positive Phase 3 studies to regulators in the fourth quarter, reinforcing expectations for future filings and product potential.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments